Carlo Acierno
Seconda Università degli Studi di Napoli
16 Papers
14 Citations
Carlo Acierno is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Type 2 diabetes & Medicine. The author has an hindex of 7, co-authored 14 publications.
Chat about Author
Papers
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy.
Raffaele Galiero,Pia Clara Pafundi,Riccardo Nevola,Luca Rinaldi,Carlo Acierno,Alfredo Caturano,Teresa Salvatore,Luigi Elio Adinolfi,Ciro Costagliola,Ferdinando Carlo Sasso +9 more
TL;DR: National and international guidelines should consider its inclusion in their updates, and the deployment of device and digital application used to increase screening of individuals and monitor progression of retinal disease needs to be easily accessible to general practitioners.
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Alfredo Caturano,Carlo Acierno,Riccardo Nevola,Pia Clara Pafundi,Raffaele Galiero,Luca Rinaldi,Teresa Salvatore,Luigi Elio Adinolfi,Ferdinando Carlo Sasso +8 more
- 11 Jan 2021
TL;DR: The role of diet, intestinal microbiota, genetic and epigenetic factors, low-degree chronic systemic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress on NAFLD have been addressed and its direct link with type 2 diabetes have been discussed.
High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study.
Ferdinando Carlo Sasso,Pia Clara Pafundi,Aldo Gelso,Valeria Bono,Ciro Costagliola,Raffaele Marfella,Celestino Sardu,Luca Rinaldi,Raffaele Galiero,Carlo Acierno,Chiara de Sio,Alfredo Caturano,Teresa Salvatore,Luigi Elio Adinolfi +13 more
TL;DR: A novel relationship between high HDL cholesterol and DR was observed and was confirmed in a real-life population of type 2 diabetes patients recruited in several centres in Italy.
55
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial
Vittorio Simeon,Raffaele Galiero,Alfredo Caturano,Paolo Chiodini,Luca Rinaldi,Teresa Salvatore,Miriam Lettieri,Riccardo Nevola,Celestino Sardu,Giovanni Docimo,Giuseppe Loffredo,Raffaele Marfella,Luigi Elio Adinolfi,U. Amelia,Carlo Acierno,P. Calatola,Ornella Carbonara,Giuseppe Conte,G. Corigliano,Marco Corigliano,R. D’urso,Antonia De Matteo,Luca De Nicola,N. De Rosa,Elisa Del Vecchio,Giacomo Di Giovanni,A. Gatti,Sandro Gentile,L. Gesuè,L Improta,A. LampitellaJr,A. Lampitella,A. Lanzilli,Nadia Lascar,S. Masi,Paola Mattei,V. Mastrilli,P. Memoli,Roberto Minutolo,Rodolfo Nasti,Andrew Pagano,M. Pentangelo,Edoardo Pisa,Emiliano Rossi,Ferdinando Carlo Sasso,Sabato Sorrentino,Roberto Torella,R. Troise,Paolo Trucillo,A.A. Turco,Salvatore Turco,Francesco Zibella,Laura Zirpoli +52 more
TL;DR: In this article , a post-hoc analysis of the Nephropathy in Diabetes type 2 (NID-2) study is presented, where the authors evaluate whether the number of risk factors on target associates with patient outcomes.
Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin
Carlo Acierno,Alfredo Caturano,Pia Clara Pafundi,Riccardo Nevola,Luigi Elio Adinolfi,Ferdinando Carlo Sasso +5 more
- 10 Sep 2020
TL;DR: The current knowledge of pathophysiological mechanisms underlying the close relationship between nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) is reviewed to allow the identification of new therapeutic targets for the treatment of NAFLD, currently substantially absent.